COMP <GO>
RCEL vs MDXG // PIOTROSKI F-SCORE QUALITY
Avita Medical Inc. (NASDAQ) VS. MiMedx Group Inc (NASDAQ) • 15-METRIC TALLY: RCEL 1
— MDXG 8
▲ PIOTROSKI F-SCORE QUALITY LEADER: MDXG
LAST: $16.71 (+1.27%) • MKT CAP: $516.8M
piotroski-score
4/9
LAST: $3.97 (+0.51%) • MKT CAP: $579.3M
piotroski-score
9/9
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (RCEL VS. MDXG)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | RCEL | MDXG | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 82.10% | 82.60% | -0.50 | MDXG | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | 47.20% | -82.20 | MDXG | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 6.7x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -6.23% | 12.77% | -19.00 | MDXG | /fcf-yield <GO> |
| Operating Margin | -59.40% | 15.30% | -74.70 | MDXG | /operating-margins <GO> |
| Net Profit Margin | -60.00% | 11.60% | -71.60 | MDXG | /net-margins <GO> |
| Revenue Growth (YoY) | 11.50% | 20.00% | -8.50 | MDXG | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | 6.45 | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality ACTIVE | 4/9 | 9/9 | -5.00 | MDXG | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 66.2 | 32.9 | +33.28 | RCEL | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 10.0x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $516.8M | $579.3M | -$62.5M | MDXG | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | RCEL REV | MDXG REV | RCEL GROSS % | MDXG GROSS % | RCEL FCF | MDXG FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $71.6M | $418.6M | 82.1% | 82.6% | -$32.2M | $74.0M |
| FY 2024 | $64.3M | $348.9M | 85.8% | 82.8% | -$58.1M | $66.2M |
| FY 2023 | $50.1M | $321.5M | — | — | -$38.0M | $26.8M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
RCEL // BETA —
MDXG // BETA —